In this section
@article{Molloy:2023:10.1038/s41390-022-02263-w,
author = {Molloy, EJ and Nakra, N and Gale, C and Dimitriades, VR and Lakshminrusimha, S},
doi = {10.1038/s41390-022-02263-w},
journal = {Pediatric Research},
pages = {1499--1508},
title = {Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management},
url = {http://dx.doi.org/10.1038/s41390-022-02263-w},
volume = {93},
year = {2023}
}
TY - JOUR
AB - During the SARS-CoV-2-associated infection (COVID-19), pandemic initial reports suggested relative sparing of children inversely related to their age. Children and neonates have a decreased incidence of SARS-CoV-2 infection, and if infected they manifested a less severe phenotype, in part due to enhanced innate immune response. However, a multisystem inflammatory syndrome in children (MIS-C) or paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 emerged involving coronary artery aneurysms, cardiac dysfunction, and multiorgan inflammatory manifestations. MIS-C has many similarities to Kawasaki disease and other inflammatory conditions and may fit within a spectrum of inflammatory conditions based on immunological results. More recently neonates born to mothers with SARS-CoV-2 infection during pregnancy demonstrated evidence of a multisystem inflammatory syndrome with raised inflammatory markers and multiorgan, especially cardiac dysfunction that has been described as multisystem inflammatory syndrome in neonates (MIS-N). However, there is a variation in definitions and management algorithms for MIS-C and MIS-N. Further understanding of baseline immunological responses to allow stratification of patient groups and accurate diagnosis will aid prognostication, and inform optimal immunomodulatory therapies. IMPACT: Multisystem inflammatory system in children and neonates (MIS-C and MIS-N) post COVID require an internationally recognized consensus definition and international datasets to improve management and plan future clinical trials. This review incorporates the latest review of pathophysiology, clinical information, and management of MIS-C and MIS-N. Further understanding of the pathophysiology of MIS-C and MIS-N will allow future targeted therapies to prevent and limit clinical sequelae.
AU - Molloy,EJ
AU - Nakra,N
AU - Gale,C
AU - Dimitriades,VR
AU - Lakshminrusimha,S
DO - 10.1038/s41390-022-02263-w
EP - 1508
PY - 2023///
SN - 0031-3998
SP - 1499
TI - Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management
T2 - Pediatric Research
UR - http://dx.doi.org/10.1038/s41390-022-02263-w
UR - https://www.ncbi.nlm.nih.gov/pubmed/36050390
UR - http://hdl.handle.net/10044/1/99517
VL - 93
ER -
Neonatal Medicine Research Group and Neonatal Data Analysis Unit Manager
(All research related queries)
Room G 4.3
Chelsea and Westminster Hospital
ndau@imperial.ac.uk
+44 (0)20 3315 5841
Research Communications Lead
(Communications related queries only)
dsakyi@imperial.ac.uk
